Rocuronium dosing

Phase 3Small molecule

CClare Hayes-Bradley

Rocuronium dosing is one of 3 small molecule programs targeting Rocuronium. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RocuroniumNot yet recruiting

RocuroniumPhase 3

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Rocuronium

#DrugCompanyPhaseTrials

Rocuronium dosing

CClare Hayes-Bradley

Phase 3

1 2

Atropen

FFresenius Kabi Taiwan Ltd.

Preclinical

1 3

Anectine

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Rocuronium

NCT07168252

Clinical

Trials by Indication[1]

Rocuronium1 trial

Developing a Physiology-Pharmacodynamic Model of Rocuronium Dose and Cardiac Output to Investigate the Onset Time of Neuromuscular Relaxation

Not yet recruiting·CClare Hayes-Bradley·Phase 4·NCT07168252·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rocuronium dosing. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rocuronium dosing compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rocuronium dosing. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Clare Hayes-Bradley company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CClare Hayes-Bradley

Rocuronium dosing

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Rocuronium1 trial

References

Drug Info

Quick Facts

Related News